Core Insights - The article emphasizes the importance of uncovering hidden details in financial reports and data that are often overlooked in mainstream media, aiming to provide a clearer understanding of significant companies and their market dynamics [5][9][20]. Group 1: Key Highlights of the Report - The seventh edition of "The Secrets of Companies" has gained popularity since its pre-sale in January, with a reprint now available for readers who missed the initial release [3]. - The report focuses on 12 companies that have been central to business discussions in 2025, highlighting their financial performance and the underlying stories that are not typically covered in conventional news [7][8]. - Notable companies featured include Cambrian, which briefly surpassed Moutai to become the top market cap in China's A-shares, and Pop Mart, which saw over 400% growth in overseas performance [7]. Group 2: Analytical Approach - The report breaks away from previous editions by focusing on popular companies not just for their media presence but for their significance and intrigue in the market [9]. - The editorial team aims to extract valuable insights from financial statements, interviews, and public data, rather than merely amplifying news and emotions [9][20]. - The analysis includes cash flow, revenue, and market share, while also considering the broader context of how these companies have evolved and their responses to competition and global trends [15][20]. Group 3: Themes and Trends - The report discusses the intersection of content and technology in companies like Nintendo, and the long-term implications of creating hit products as seen with Pop Mart and Bawang Tea [12]. - It highlights the challenges faced by companies like Cambrian and Horizon, which are often compared to their counterparts but may face unique commercialization challenges [12]. - The overarching theme is to provide a deeper understanding of business dynamics, emphasizing that true insights often lie beneath the surface of popular narratives [21].

Core Viewpoint - The beauty industry is undergoing a significant shift, with consumers increasingly focusing on holistic experiences and the values represented by brands, rather than just product efficacy or singular concepts [2][4][27]. Group 1: Brand Theme and Strategy - In 2026, the brand established the annual theme "Love," aiming to resonate with contemporary women's multifaceted identities and lifestyles, emphasizing self-exploration and emotional fulfillment [4][5]. - The collaboration with spokesperson Jin Jing and the launch of a new thematic TVC reflect a natural evolution from the previous "self-appreciation" narrative to a broader exploration of the connection between skincare and lifestyle [2][5][24]. Group 2: Thematic Narrative in TVC - The TVC narrative unfolds across three real-life scenarios: workplace focus, solitude, and social connection, with the core imagery of "upward high-five" symbolizing both skin vitality and emotional growth [5][10][12]. - Each scenario emphasizes that every moment can serve as a pivot for upward growth, linking skincare to self-affirmation and emotional well-being [12][28]. Group 3: Professional and Scientific Backing - The brand's parent company, Juzi Biotechnology, holds multiple Class III medical device registrations, indicating high technical barriers and robust research capabilities, which support the anti-aging efficacy of its products [15][27]. - This scientific foundation reinforces the brand's narrative of "upward" not just as an emotional expression but as a concept backed by research and technology [15][33]. Group 4: Consumer Engagement and Cultural Resonance - The brand's approach to "Love" reflects a shift towards valuing the process of self-care and emotional well-being, rather than merely focusing on results [27][28]. - Collaborations with platforms like Douyin and Xiaohongshu further embed the theme of "Love" into everyday narratives, emphasizing that love exists in ordinary moments rather than grand gestures [24][26]. Group 5: Brand Evolution and Market Positioning - The transition from "self-appreciation" to "Love" illustrates the brand's ongoing narrative centered around human experiences, moving from product efficacy to a deeper connection with consumers' emotional states [30][33]. - As the beauty industry shifts towards a balance of technological strength and value expression, the brand aims to be a companion in consumers' journeys of self-discovery and affirmation [27][34].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 GIANT BIOGENE HOLDING CO., LTD 董事會主席 嚴建亞 中 國 西 安，2026年3月5日 截至本公告日期，董事會成員包括執行董事嚴建亞先生、葉娟女士、方娟女士、 張 慧 娟 女 士 及 嚴 鈺 博 女 士 以 及 獨 立 非 執 行 董 事 黃 進 先 生、單 文 華 先 生 及 黃 斯 穎 女 士。 巨子生物控股有限公司 巨子生物控股有限公司（「本公司」及 其 附 屬 公 司「本集團」）董事會（「董事會」）兹 通告謹定於2026年3月19日（星 期 四）舉 行 董 事 會 會 議，以 考 慮 及 通 過 本 集 團 截 至 2025年12月31日 止 的 年 度 全 年 業 績，及 建 議 之 末 期 股 息（如 有），以 及 處 理 其 他 事 項。 承董事會命 巨子生物控股有限公司 （於 開 曼 群 島 註 冊 成 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 巨子生物控股有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 根據《主板上市規則》 ...

Summary of China Cosmetics Conference Call Industry Overview - The focus is on the **anti-aging beauty market** in China, which includes traditional anti-aging skincare, medical aesthetics (MA), and dermocosmetics. - The market is expected to grow at a **high single-digit CAGR** over the period from 2025 to 2030, with medical aesthetics and dermocosmetics leading at **9%** and anti-aging skincare at **6%** [1][22]. Key Insights Market Penetration and Demographics - The current penetration of the MA market in China is low, estimated at **5%** for the core consumer group aged **20-60**, compared to **10%-20%** in developed markets. It is expected to rise to **8%** by **2030E**, supporting a **10% CAGR** for MA users [2][22]. - Anti-aging skincare is seeing earlier adoption among younger consumers, with approximately **40%** of this demographic engaging with the category, which is expected to drive further expansion [2][22]. Pricing Dynamics - More resilient pricing is anticipated from **2026E** due to stricter regulations and healthier competition, with limited supply tailwinds favoring recombinant collagen. The MA market has experienced sharp price reductions due to intense competition, but future pricing is expected to stabilize [3][22]. - Factors contributing to this stabilization include more accessible pricing in China and a narrower price gap with Korea following recent policy changes [3][22]. Company Recommendations - **Forest Cabin** is initiated with a **Buy** rating, expected to benefit from growth in oil-based anti-aging skincare, with a projected **48% sales CAGR** from **2022-2025E** and **32%/29% sales/NP CAGR** from **2025-2028E** [4][22]. - **Giant Biogene** is also rated **Buy** due to its integrated value chain from MA to dermocosmetics, enhancing R&D and brand recognition [4][22]. - **Proya** is viewed as a domestic leader in the anti-aging sector but is rated **Neutral** pending further evidence of the new management's execution track record [4][22]. Market Growth Projections - The overall anti-aging market in China is projected to grow from **RMB 214 billion** in **2024E** to **RMB 398 billion** by **2030E**, reflecting a **CAGR of 8%** [20][22]. - Medical aesthetics is expected to contribute significantly to this growth, with a **10.3% volume CAGR** over the same period, despite ongoing pricing pressures in certain categories [17][22]. Additional Insights - The report emphasizes the importance of companies with larger sales exposure to growth segments, stronger market positions, and better operational execution, including R&D capabilities [10][22]. - The anti-aging skincare segment is projected to see a shift towards functionalities beyond basic moisturizing, with penetration expected to increase from **25.6% to 29.0%** from **2025 to 2030E** [19][22]. Conclusion - The anti-aging beauty market in China presents significant growth opportunities driven by demographic shifts, evolving consumer perceptions, and technological advancements. Companies like Forest Cabin and Giant Biogene are well-positioned to capitalize on these trends, while pricing dynamics and market penetration will play crucial roles in shaping the competitive landscape.

Group 1: Medical Aesthetics Industry - The Chinese medical aesthetics market is expected to reach nearly 370 billion yuan by 2025, with a compound annual growth rate (CAGR) of approximately 10% projected until 2030, potentially reaching 600 billion yuan [2][8][36] - The trend of "self-pleasure consumption" is prominent, with about 50% of users indicating that the reason for choosing medical aesthetics is that "becoming beautiful makes them happier" [8][11][15] - The consumer demographic is shifting towards younger individuals, with the proportion of users under 25 years old increasing from 26% in 2022 to 35% by 2025 [20][22][36] - Light medical aesthetics are becoming mainstream, accounting for 52% of the market in 2022, with a growing preference for non-invasive procedures [16][17][36] - The market for recombinant collagen is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, potentially reaching 114.5 billion yuan [8][45] Group 2: Beauty Industry - The retail sales of cosmetics in China are projected to grow at a CAGR of approximately 9% from 2016 to 2024, with a moderate recovery expected in 2025 [3][9] - The trend of "self-gifting" is becoming the primary scenario for beauty consumption, reflecting the strengthening of "self-pleasure consumption" [3][8] - The cosmetics raw materials market is expected to grow from 1147.8 billion yuan in 2019 to 1603.9 billion yuan by 2024, with a CAGR of 6.9% [3][9] - The ODM (Original Design Manufacturer) industry for cosmetics is projected to reach 62.29 billion yuan by 2025, with domestic brands gaining market share [3][9] Group 3: Related Companies on the Beijing Stock Exchange - Companies such as Jinbo Biological, which leads in recombinant collagen medical devices and is entering the functional skincare market, are expected to benefit from the ongoing growth in the beauty consumption sector [3][8] - Bawei Co., which provides ODM services for domestic and international cosmetic brands, is also positioned to gain from the industry's expansion [3][8] - Leading companies in cosmetic raw materials, such as Weiqi Technology and Jiakai Biological, are well-placed to capitalize on the industry's growth [3][8]

Group 1: Insurance Sector - Insurance stocks are experiencing significant declines, with China Life (02628) down 3.75%, New China Life (01336) down 3.28%, and China Pacific Insurance (02601) down 2.74%. The government plans to issue approximately 200 billion yuan in special bonds to inject capital into major insurance companies, marking the first time this method will be used for insurance firms in China [1] Group 2: Logistics and Delivery - ZTO Express (02057) has seen an increase of over 2.3%. The company estimates that its total revenue for 2025 will be between 48.5 billion yuan and 50 billion yuan, representing a growth of approximately 9.5% to 12.9% compared to 44.2807 billion yuan in 2024 [1] Group 3: Biotechnology - Innovent Biologics (09969) has risen over 4%, with a current increase of 3.25%. The company anticipates achieving revenue of 2.37 billion yuan in 2025, a year-on-year growth of approximately 134%, and expects to turn a profit with a net profit of around 630 million yuan [1] Group 4: Coal Sector - Coal stocks are generally declining, with Yancoal Australia (03668) down 6.63%, Shougang Resources (00639) down 7.83%, and China Shenhua (01088) down 2.47%. This decline follows reports that the Indonesian government has proposed a production cut plan, leading to a 40% to 70% reduction in production quotas for major miners [2] Group 5: Medical Devices - GigaGen (02367) has increased over 8%, currently up 4.11%. The company recently announced that its "recombinant type I α1 collagen and sodium hyaluronate composite solution" has been approved as a medical device, marking a significant milestone as the first product of its kind for improving facial smoothness [2] Group 6: Semiconductor Sector - Semiconductor stocks are all declining, with Hua Hong Semiconductor (01347) down 5.91% and SMIC (00981) down 3.49%. This follows a significant drop in AMD's stock price by 17.31% after its fourth-quarter report indicated that while revenue exceeded expectations, the guidance for the first quarter was below market expectations [3] Group 7: Restaurant Sector - Restaurant stocks are performing well, with Yum China (09987) up 8.41% and Haidilao (06862) up 2.69%. The restaurant industry has shown signs of recovery, with retail sales in the sector growing by 3.8%, 3.2%, and 2.2% year-on-year in the last quarter of 2025, significantly outpacing overall retail growth [3] Group 8: Consumer Goods - Miniso (09896) has risen over 5.1% after announcing its partnership with the Central Radio and Television Station for the 2026 Spring Festival Gala. This collaboration is seen as a significant marketing move to elevate the brand's visibility in the mainstream market [4] Group 9: Gold Sector - Gold stocks are declining, with China Gold International (02099) down 6.8% and Zijin Mining (02899) down 6.29%. Recent volatility in the international gold market has been noted, with expectations that geopolitical tensions and liquidity easing by the Federal Reserve may drive gold prices higher [4] Group 10: Cryptocurrency - Cryptocurrency ETFs and related stocks are continuing to decline, with significant drops in prices, including Bitcoin falling below $72,000 for the first time in 15 months. The price has decreased by over 42% from its peak last October [5] Group 11: US Market Highlights - Boston Scientific (BSX.US) fell 17.59% after providing lower-than-expected guidance for fiscal year 2026. The company expects adjusted earnings per share to be between $3.43 and $3.49, slightly below analyst expectations [6] - Solar stocks surged, with Enphase Energy (ENPH.US) rising 38.6% following reports of interest from Elon Musk's teams in the Chinese solar supply chain [6]

Group 1 - The stock of Giant Bio (02367.HK) increased by over 8% during the trading session, with a current rise of 7.03% to HKD 34.4 [1] - The trading volume reached HKD 256 million [1]

Group 1 - The core viewpoint of the article highlights that Giant Bio (02367) has seen a significant stock price increase, with a rise of over 8% during trading, currently at 34.4 HKD, with a trading volume of 256 million HKD [1] - Giant Bio recently announced the approval of its "recombinant type I α1 collagen and sodium hyaluronate composite solution" as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness through a combined implant solution [1] - CICC expresses optimism regarding the approval of this product, which is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Group 2 - Looking ahead, CICC believes that the company's research and development strength, brand recognition, and team cohesion remain solid, suggesting that there are opportunities for investment as the cosmetics market recovers and contributions from aesthetic medicine increase [1]

Group 1 - The core viewpoint of the article highlights that Giant Bio (02367) has seen a significant stock price increase, with a rise of over 8% during trading, currently at 34.4 HKD and a trading volume of 256 million HKD [1] - Giant Bio recently announced the approval of its "recombinant type I α1 collagen and sodium hyaluronate composite solution" as a Class III medical device, marking it as the world's first implant product aimed at improving cheek smoothness [1] - CICC expresses optimism regarding the product's approval, which is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Group 2 - The long-term outlook from CICC suggests that the company's research and development strength, brand recognition, and team cohesion remain solid [1] - As the cosmetics market recovers and the contribution from aesthetic medicine increases, CICC recommends paying attention to investment opportunities in the company [1]